Research for PSP
Research activities into the cause, treatment and cure of PSP are ongoing in Australia and overseas. Most research activities do require recruitment of patients. Parkinson’s Australia will often have information about these trials and studies. Your doctor or neurologist would ultimately decide if you are suitable for entry to these studies. Contact Parkinson’s Australia on 1800 644 189.
The Australian Brain Bank Network collects details of patients interested in leaving their brain for scientific research. Visit www.nnf.com.au/platforms/abbn 
or telephone (03) 8344 1900.
Information about PSP research overseas may be available by visiting some of the international PSP websites listed in our Useful links section.
Associations
Allon Therapeutics Inc. has initiated a clinical trial using davunetide, an investigational treatment, in patients with Progressive Supranuclear Palsy (PSP). The purpose of this Phase 2/3 study is to assess the safety and efficacy of davunetide as a potential treatment for patients with PSP.
This study is currently enrolling patients with probable or possible PSP who are 41-85 years old. The goal of the study is to test whether davunetide is safe and effective in helping patients with PSP. Approximately 300 patients will take part in the study in centers across the USA, Canada, Europe and Australia. This is a placebo controlled study which means half of the patients on the study will receive the study drug and the other half will receive a placebo which looks the same as the study drug but has no active ingredients.
Additional details about this study, including information on participating study centers can be found here. Those interested in taking part in this study should contact the study site closest to you.
The Australian contact for this trial is: Sue Varley, 03 9076 5187, email: s.varley@alfred.org.au Sus is Assoc Prof. David Williams' movement disorders nurse.
